General Surgery Center, Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center for Artificial Organ and Tissue Engineering, Guangzhou Clinical Research and Transformation Center for Artificial Liver, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Department of General Surgery II, The First People's Hospital of Zhaoqing, Zhaoqing, China.
J Cell Mol Med. 2022 Jul;26(13):3598-3607. doi: 10.1111/jcmm.17407. Epub 2022 Jun 3.
LECT2 (leucocyte cell-derived chemotaxin 2) is a 16-kDa protein mainly produced by hepatocytes. It was first isolated in PHA-activated human T-cell leukaemia SKW-3 cells and originally identified as a novel neutrophil chemotactic factor. However, many lines of studies suggested that LECT2 was a pleiotropic protein, it not only functioned as a cytokine to exhibit chemotactic property, but also played multifunctional roles in some physiological conditions and pathological abnormalities, involving liver regeneration, neuronal development, HSC(haematopoietic stem cells) homeostasis, liver injury, liver fibrosis, hepatocellular carcinoma, metabolic disorders, inflammatory arthritides, systemic sepsis and systemic amyloidosis. Among the above studies, it was discovered that LECT2 could be a promising molecular biomarker and therapeutic target. This review summarizes LECT2-related receptors and pathways, basic and clinical researches, primarily in mice and human, for a better comprehension and management of these diseases in the future.
LECT2（白细胞细胞衍生趋化因子 2）是一种 16kDa 的蛋白质，主要由肝细胞产生。它最初在 PHA 激活的人类 T 细胞白血病 SKW-3 细胞中被分离出来，并最初被鉴定为一种新型的中性粒细胞趋化因子。然而，许多研究表明，LECT2 是一种多功能蛋白，它不仅作为细胞因子发挥趋化作用，而且在某些生理条件和病理异常中发挥多种功能，涉及肝再生、神经元发育、HSC（造血干细胞）稳态、肝损伤、肝纤维化、肝细胞癌、代谢紊乱、炎症性关节炎、全身败血症和系统性淀粉样变性。在上述研究中，发现 LECT2 可能是一种很有前途的分子生物标志物和治疗靶点。本综述总结了 LECT2 相关的受体和途径、基础和临床研究，主要在小鼠和人类中，以便更好地理解和管理这些疾病。
